So far, the wonders of chimeric antigen receptor (CAR) T-cell therapy have only been seen in blood cancers. Investigators at Moffitt Cancer Center report findings that show a potential target in solid tumors.
Investigators from Moffitt Cancer Center in Tampa, Florida, have published results identifying a potential target for chimeric antigen receptor (CAR) T-cell therapies in solid tumors—which could be step toward bringing this game-changing treatment beyond blood cancers.
In Molecular Cancer Therapeutics, a publication of the American Association of Cancer Research, the Moffitt team present the identification of OR2H1, an olfactory receptor that they demonstrate inhibits growth in lung and ovarian tumors.
The creation of individualized CAR T-cell therapy involves genetic modification of a patient’s own T cells, which are collected through apheresis and then put through a manufacturing process; the cells are modified to include a gene for the T cell receptor that allow them to hunt down the cancer in the body when the treatment is infused back into the patient.
Finding tumor markers that will make this process work in solid tumors has been a huge challenge. The Moffitt team, led by Jose Conejo-Garcia, MD, PhD, has zoned in on proteins—the olfactory receptors—that are expressed in the nose but are also found in many solid tumors, and very few normal cells.
The investigators created CAR T cells specific to the OR2H1 protein, which were able to kill lung and ovarian cells that expressed OR2H1—but did nothing to healthy cells. The same effect was seen in mice implanted with human tumors with varying levels of OR2H1.
“Our work demonstrates the applicability of this therapy to a wide variety of patients, given the expression of OR2H1 in a subset of solid tumors across multiple histologies, including high-grade serous ovarian cancers, lung carcinoma, cholangiocarcinoma, prostate cancer and ovarian cancers of multiple other histologies,” Conejo-Garcia, chair of Moffitt’s Department of Immunology, said in a statement. “Targeting a molecule that is not expressed in vital tissues would allow us to further engineer T cells to overcome immunosuppression at tumor beds, if needed.”
Reference
Martin AL, Anadon CM, Biswas S, et al. Olfactory receptor OR2H1 is an effective target for CAR T cells in human epithelial tumors. Mol Cancer Ther. Published online May 2, 2022. https://doi.org/10.1158/1535-7163.MCT-21-0872
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen